[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please click [here]( [9k=] --------------------------------------------------------------- [Did Biden Bet the Future of America on the "Lithium Triangle"?]( [Discover the one company set to break China's grip on lithium.]([aff_i?offer_...] --------------------------------------------------------------- August 11, 2022 From the desk of the Editor (5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers of all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- [5X Potential Growth By 2030? Is This Little-Known Market About To Explode?]( [2b21c224-d46...](It's used for our BELOVED Air Force's fighter jets, cell phones, and wind turbines. And soon, you're going to hear about it everywhere... because according to renowned intelligence reports... [Demand Will EASILY 5X By 2030! (Discover It HERE!)]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Verona Pharma, VRNA]( Recent Analyst Action: Joon Lee, analyst at Truist Financial, reiterates coverage on [Verona Pharma (VRNA)](in the Healthcare sector with a Buy rating and a price target of $20 (1 day ago). - Recent Price: $12 - Average Analyst Price Target: $22.67 (88.92%) - Market Cap: $664.40M [TipRanks.com]( also reports that [Verona Pharma](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $22.67. The target pricing ranges from a high forecast of $25.00 down to a low forecast of $20.00. [Verona Pharma (VRNA)](’s last closing price was $$12 which would put the average price target at $22.67. Here are 3rd party ratings for [VRNA](: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 33% (82 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Crypto Is Dead... i.e. The Dumbest Prediction in History]( [e9514312-b91...](Back in the late 1990s the mainstream media called the internet “dead.” That was the dumbest prediction in history… until now. Because now, the same “geniuses” who said the internet was dead are ringing death bells for crypto. And as you’ll see from this riveting interview with a former Goldman Sachs executive… a whole lot of savvy investors are going to get very rich and have the last laugh. [Go here to watch.](//trailer.web-view.net/Links/0X42E30EFAB03E9D306F1FDE6788CBE72EEEECD1CF4C05F0DCFD52A12E95B9F9D672643B619217AF222C62457C814201B2E58A4FADC9EF9F7F97B78C110EC8F65BF598CD369566B7DD.htm [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Heron Therapeutics, HRTX]( Recent Analyst Action: Boris Peaker, analyst at Cowen & Co., reiterates coverage on [Heron Therapeutics (HRTX)](in the Healthcare sector with a Buy rating and a price target of $5.5 (2 days ago). - Recent Price: $4.855 - Average Analyst Price Target: $7.75 (59.63%) - Market Cap: $481.65M [TipRanks.com]( also reports that [Heron Therapeutics](currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $7.75. The target pricing ranges from a high forecast of $10.00 down to a low forecast of $5.50. [Heron Therapeutics (HRTX)](’s last closing price was $$4.855 which would put the average price target at $7.75. Here are 3rd party ratings for [HRTX](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 35% (87 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- [Gamida Cell, GMDA]( Recent Analyst Action: Vernon Bernardino, analyst at H.C. Wainwright, reiterates coverage on [Gamida Cell (GMDA)](in the Healthcare sector with a Buy rating (1 day ago). - Recent Price: $2.91 - Average Analyst Price Target: $16.50 (404.12%) - Market Cap: $158.36M [TipRanks.com]( also reports that [Gamida Cell](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $16.50. The target pricing ranges from a high forecast of $22.00 down to a low forecast of $12.00. [Gamida Cell (GMDA)](’s last closing price was $$2.91 which would put the average price target at $$14.67. Here are 3rd party ratings for [GMDA](: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 33% (82 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast: ["Prepare for Five Years of Famine"]( [Screen+Shot+...]( [Click here]( for the name of the one ticker you need to protect yourself.[5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [Atara Biotherapeutics, ATRA]( Recent Analyst Action: Tommie Reerink, analyst at Goldman Sachs, reiterates coverage on [Atara Biotherapeutics (ATRA)](in the Healthcare sector with a Sell rating and a price target of $3 (2 days ago). - Recent Price: $4.88 - Average Analyst Price Target: $20.38 (317.62%) - Market Cap: $462.36M [TipRanks.com]( also reports that [Atara Biotherapeutics](currently has 8 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $20.38. The target pricing ranges from a high forecast of $50.00 down to a low forecast of $3.00. [Atara Biotherapeutics (ATRA)](’s last closing price was $4.88 which would put the average price target at $20.38. Here are 3rd party ratings for [ATRA](: - TipRanks.com: Hold - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Buy, Top 33% (82 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- [Scholar Rock Holding, SRRK]( Recent Analyst Action: Gary Nachman, analyst at BMO Capital, reiterates coverage on [Scholar Rock Holding (SRRK)](in the Healthcare sector with a Buy rating and a price target of $43 (2 days ago). - Recent Price: $10.03 - Average Analyst Price Target: $29.75 (196.61%) - Market Cap: $521.96M [TipRanks.com]( also reports that [Scholar Rock Holding](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $29.75. The target pricing ranges from a high forecast of $43.00 down to a low forecast of $19.00. [Scholar Rock Holding (SRRK)](’s last closing price was $10.03 which would put the average price target at $29.75. Here are 3rd party ratings for [SRRK](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Buy, Top 33% (82 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Will This Be the Worst U.S. Crisis Ever?]( [b9dbbf1c-e7c...](Wealthy 73-year-old U.S. entrepreneur retreats to one of his three European properties to issue serious warning (and 4 recommendations) for Americans. "It falls on someone like me to warn you clearly. I'm too rich to care about money—and too old to care what anyone thinks." [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [AbSci, ABSI]( Recent Analyst Action: Robyn Karnauskas, analyst at Truist Financial, reiterates coverage on [AbSci (ABSI)](in the Services sector with a Buy rating and a price target of $8 (3 weeks ago). - Recent Price: $5.3 - Average Analyst Price Target: n/a (164.15%) - Market Cap: $389.98M [TipRanks.com]( also reports that [AbSci](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $14.00. The target pricing ranges from a high forecast of $28.00 down to a low forecast of $8.00. [AbSci (ABSI)](’s last closing price was $5.3 which would put the average price target at $14.00. Here are 3rd party ratings for [ABSI](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 33% (82 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- [IGM Biosciences, IGMS]( Recent Analyst Action: Robert Burns, analyst at H.C. Wainwright, reiterates coverage on [IGM Biosciences (IGMS)](in the Healthcare sector with a Buy rating and a price target of $58 (2 days ago). - Recent Price: $25.62 - Average Analyst Price Target: $44.50 (73.69%) - Market Cap: $1.10B [TipRanks.com]( also reports that [IGM Biosciences](currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $44.50. The target pricing ranges from a high forecast of $58.00 down to a low forecast of $31.00. [IGM Biosciences (IGMS)](’s last closing price was $25.62 which would put the average price target at $44.50. Here are 3rd party ratings for [IGMS](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 33% (82 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry?]( [a4f92c65-722...](You've never heard of this rare metal. But it's CRITICAL for our fighter jets, missiles, and military vehicles. The bad news is, Communist China has a MONOPOLY on this critical resource... [But Trump AND Biden's Executive Orders Could Change That, And Trigger A Boom For Investors](//trailer.web-view.net/Links/0X1D9BA5B0FDB32C9ABAEE184D46104802AA27CC0A698EC64419D892AD0BD0232B4C6A9D476C10852C2C62457C814201B2E58A4FADC9EF9F7F97B78C110EC8F65BF598CD369566B7DD.htm [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- And there you have it--7 Five Day Gainers of all US Exchanges. Sincerely, Editor, MarketMoversInsider.com Disclaimer This email/newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this email/newsletter is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this email/newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our email/newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. MarketMoversInsider.com | PO Box 407 | Mt. Mourne | North Carolina | 28123 | United States | 8458030954 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software